ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1850

Association of Clinical Trial Characteristics with Positive Study Outcome Reporting in Randomized Controlled Trials of Rheumatoid Arthritis Therapy

Fatima M. Khan1, Juan I. Lombeida2, Horace Spencer3, Karina D. Torralba4, Winnie K. Pang4 and Nasim A. Khan5, 1Rheumatology/Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 2Mercy Medical Center, Rogers, AR, 3University of Arkansas for Medical Sciences, Little Rock, AR, 4Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 5Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: clinical trials, funding and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Randomized controlled trials (RCTs) are considered the best research design for assessing healthcare intervention. Concerns have been raised about the increased likelihood of positive RCT outcome (bias) with trial characteristics such as financial conflicts of interests (FCOIs) and inadequate methodological quality parameters reporting. Our objective was to assess whether reported trial characteristics are associated with outcome of RCTs of rheumatoid arthritis (RA) drug therapy.

Methods: We identified original, non-phase 1, parallel-group, drug therapy RCTs of RA published in English in the years 2002-3, 2006-7, and 2010-11 by searching Medline and CENTRAL databases. RCT efficacy was assessed for primary outcome as positive (statistically significant result favoring experimental intervention) or negative. RCT characteristics [experimental intervention (traditional anti-rheumatic drugs, biologics, small molecules, others), study phase (phase 2, non-phase 2), funding source (industry, non-profit), FCOIs of authors related to industry sponsor (honoraria/consultation fee, employment, research grant, stock ownership), number of subjects enrolled, study center (single, multiple), study duration, and placebo use], and reported methodological quality measures [adequate description of random sequence generation, allocation concealment, blinding, subject follow-up, intent-to-treat analysis] were assessed independently by two investigators. Univariable associations of trial characteristics and methodological quality measures with positive study outcome were assessed using Chi-square, Fisher’s exact test, likelihood ratio, or t-test. Multivariable logistic regression (MLR) was performed by including funding source and all variables associated with positive outcome with P≤0.1

Results: 146 eligible RCTs were identified. Efficacy outcome could be assessed for 125 (85.6%) RCTs. Studies were excluded for the following reasons:  primary outcome safety (11), no intervention declared experimental a priori(10). Positive outcome was noted in 86 (68.8%) RCTs. Non-phase 2, higher number of enrolled patients and author FCOI (honoraria/consultation fee) increased likelihood, while adequate random sequence generation description decreased this likelihood of positive outcome on univariable analysis. Author FCOI (honoraria/consultation fee), number of enrolled patients, and adequate description of randomization were independently associated with positive outcomes in MLR analysis (Table 1).

Conclusion: Certain trial characteristics (number of enrolled subjects, author’s receipt of honoraria/consultation fee) and reported trial quality measure (random sequence generation description) were independently associated with positive outcomes of RA drug therapy RCTs.

Table 1. Univariable and multivariable analysis of clinical trial characteristics and study outcome.

Variable

Univariable analysis

Multivariable analysis

Referent

 

OR (95% CI)*

P

OR (95% CI)*

P

Funding source, industry**

Non-profit

0.89 (0.40-1.97)

0.769

0.53 (0.18-1.53)

0.241

Honoraria/consulting fee receipt by author, yes

No

2.41 (0.99-5.88)

0.043

3.24 (1.06-9.88)

0.039

Non-phase 2

Phase 2

3.45 (1.41-8.45)

0.005

2.68 (0.88-8.11)

0.082

Number of patient enrolled***

D 1

1.59 (1.09-2.32)

0.013

1.73 (1.11-2.69)

0.016

Duration of study, months***

D 1

1.49 (0.95-2.32)

0.075

1.28 (0.78-2.10)

0.321

Adequate reporting of random sequence generation, yes

No

0.40 (0.18-0.89)

0.022

0.32 (0.13-0.78)

0.013

 

*OR: odds ratio; CI: confidence interval

*RCTs with partial or complete funding by industry were considered as industry funded, while those with explicit non-profit source or unspecified funding source were considered non-profit.

**log transformed


Disclosure:

F. M. Khan,
None;

J. I. Lombeida,
None;

H. Spencer,
None;

K. D. Torralba,
None;

W. K. Pang,
None;

N. A. Khan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-clinical-trial-characteristics-with-positive-study-outcome-reporting-in-randomized-controlled-trials-of-rheumatoid-arthritis-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology